Biogen Inc. (BIIB) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $186.69 (-1.27%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 19, 2026 | Emily Field | Barclays | $185.00 | -0.9% |
| Feb 10, 2026 | Laura Chico | Wedbush | $187.00 | +0.2% |
| Feb 9, 2026 | Danielle Brill | Truist Financial | $193.00 | +3.4% |
| Feb 9, 2026 | Andrew Fein | H.C. Wainwright | $228.00 | +22.1% |
| Feb 9, 2026 | Yatin Suneja | Guggenheim | $246.00 | +31.8% |
| Feb 9, 2026 | William Pickering | Tudor Pickering | $201.00 | +7.7% |
| Feb 8, 2026 | Terence Flynn | Morgan Stanley | $190.00 | +1.8% |
| Feb 6, 2026 | Evan Seigerman | BMO Capital | $196.00 | +5.0% |
| Jan 30, 2026 | Jay Olson | Oppenheimer | $225.00 | +20.5% |
| Jan 8, 2026 | Salveen Richter | Goldman Sachs | $225.00 | +20.5% |
| Dec 12, 2025 | Terence Flynn | Morgan Stanley | $156.00 | -16.4% |
| Nov 3, 2025 | William Pickering | Tudor Pickering | $157.00 | -15.9% |
| Sep 25, 2025 | Andrew Tsai | Jefferies | $190.00 | +1.8% |
| Jun 25, 2025 | Brian Abrahams | RBC Capital | $213.00 | +14.1% |
| May 5, 2025 | Andrew Fein | H.C. Wainwright | $187.00 | +0.2% |
| May 2, 2025 | Jay Olson | Oppenheimer | $205.00 | +9.8% |
| Feb 13, 2025 | Sumant Kulkarni | Canaccord Genuity | $265.00 | +41.9% |
| Feb 12, 2025 | Ami Fadia | Needham | $270.00 | +44.6% |
| Feb 12, 2025 | Geoff Meacham | Citigroup | $160.00 | -14.3% |
| Feb 12, 2025 | Mohit Bansal | Wells Fargo | $165.00 | -11.6% |
Top Analysts Covering BIIB
BIIB vs Sector & Market
| Metric | BIIB | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.67 | 2.24 | 2.41 |
| Analyst Count | 40 | 8 | 18 |
| Target Upside | +13.3% | +1150.3% | +14.9% |
| P/E Ratio | 1.20 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $2.32B | $2.39B | $2.51B | 20 |
| 2026-09-30 | $2.32B | $2.40B | $2.51B | 10 |
| 2026-12-31 | $9.48B | $9.66B | $10.13B | 22 |
| 2027-03-31 | $2.42B | $2.51B | $2.64B | 10 |
| 2027-06-30 | $2.54B | $2.64B | $2.78B | 9 |
| 2027-09-30 | $2.57B | $2.66B | $2.80B | 9 |
| 2027-12-31 | $2.59B | $2.69B | $2.83B | 17 |
| 2028-03-31 | $2.83B | $2.94B | $3.09B | 15 |
| 2028-06-30 | $2.79B | $2.89B | $3.04B | 10 |
| 2028-09-30 | $2.82B | $2.93B | $3.08B | 8 |
| 2028-12-31 | $2.79B | $2.90B | $3.05B | 8 |
| 2029-12-31 | $9.89B | $10.35B | $11.11B | 14 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $3.29 | $4.30 | $4.93 | 21 |
| 2026-09-30 | $4.09 | $4.27 | $4.53 | 9 |
| 2026-12-31 | $13.83 | $15.21 | $16.59 | 18 |
| 2027-03-31 | $3.33 | $3.50 | $3.73 | 9 |
| 2027-06-30 | $4.27 | $4.48 | $4.78 | 8 |
| 2027-09-30 | $4.31 | $4.53 | $4.83 | 8 |
| 2027-12-31 | $4.47 | $4.69 | $5.01 | 16 |
| 2028-03-31 | $6.07 | $6.37 | $6.80 | 16 |
| 2028-06-30 | $5.86 | $6.15 | $6.56 | 11 |
| 2028-09-30 | $5.74 | $6.02 | $6.42 | 9 |
| 2028-12-31 | $6.24 | $6.55 | $6.99 | 9 |
| 2029-12-31 | $18.47 | $19.61 | $21.48 | 2 |
Frequently Asked Questions
What is the analyst consensus for BIIB?
The consensus among 40 analysts covering Biogen Inc. (BIIB) is Hold with an average price target of $207.60.
What is the highest price target for BIIB?
The highest price target for BIIB is $415.00, set by Steve Chesney at Atlantic Equities on 2021-06-08.
What is the lowest price target for BIIB?
The lowest price target for BIIB is $156.00, set by Terence Flynn at Morgan Stanley on 2025-12-12.
How many analysts cover BIIB?
40 analysts have issued ratings for Biogen Inc. in the past 12 months.
Is BIIB a buy or sell right now?
Based on 40 analyst ratings, BIIB has a consensus rating of Hold (2.67/5) with a +13.3% upside to the consensus target of $207.60.
What are the earnings estimates for BIIB?
Analysts estimate BIIB will report EPS of $4.30 for the period ending 2026-06-30, with revenue estimated at $2.39B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.